Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The HOPE trial convinced many experts that midlife adults (age ≥ 55 years) with existing vasculopathy (history of CAD, CVD, diabetes and CV risk factors) will have improved outcomes on an ACE inhibitor (ramipril, to be specific).

Clinical Briefs by Louis Kuritzky, MD